Ieq Capital LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 215.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 46,018 shares of the medical research company’s stock after acquiring an additional 31,451 shares during the period. Ieq Capital LLC’s holdings in Amgen were worth $19,397,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also recently made changes to their positions in AMGN. Focus Advisor Solutions LLC lifted its stake in Amgen by 96.8% in the third quarter. Focus Advisor Solutions LLC now owns 12,846 shares of the medical research company’s stock valued at $5,415,000 after buying an additional 6,319 shares during the period. 360 Financial Inc. grew its position in shares of Amgen by 15.2% during the 3rd quarter. 360 Financial Inc. now owns 2,347 shares of the medical research company’s stock worth $989,000 after buying an additional 310 shares during the period. Alpha Financial Partners LLC grew its position in shares of Amgen by 8.7% during the 3rd quarter. Alpha Financial Partners LLC now owns 686 shares of the medical research company’s stock worth $289,000 after buying an additional 55 shares during the period. Frisch Financial Group Inc. increased its stake in shares of Amgen by 2.4% in the 3rd quarter. Frisch Financial Group Inc. now owns 1,416 shares of the medical research company’s stock valued at $597,000 after acquiring an additional 33 shares in the last quarter. Finally, OneAscent Family Office LLC increased its stake in shares of Amgen by 22.5% in the 3rd quarter. OneAscent Family Office LLC now owns 1,071 shares of the medical research company’s stock valued at $452,000 after acquiring an additional 197 shares in the last quarter. 76.50% of the stock is owned by institutional investors.
Amgen Trading Down 0.8%
NASDAQ AMGN opened at $435.52 on Friday. The company has a market cap of $235.58 billion, a price-to-earnings ratio of 25.26, a P/E/G ratio of 3.22 and a beta of 0.43. Amgen Inc. has a 52 week low of $312.39 and a 52 week high of $483.99. The business has a 50 day moving average price of $430.44 and a 200-day moving average price of $383.81. The company has a quick ratio of 1.20, a current ratio of 1.48 and a debt-to-equity ratio of 3.60.
Amgen (NASDAQ:AMGN – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.79 by $0.66. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The company had revenue of $10.37 billion for the quarter, compared to analysts’ expectations of $10.07 billion. During the same period last year, the business earned $5.64 EPS. Amgen’s quarterly revenue was up 8.5% compared to the same quarter last year. As a group, equities analysts expect that Amgen Inc. will post 23.41 earnings per share for the current fiscal year.
Amgen Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Friday, November 20th. Amgen’s dividend payout ratio is currently 58.47%.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on the stock. Citigroup boosted their target price on shares of Amgen from $405.00 to $465.00 and gave the company a “neutral” rating in a research report on Wednesday, November 4th. Morgan Stanley raised their price target on shares of Amgen from $359.00 to $410.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 4th. Canaccord Genuity Group lifted their price target on shares of Amgen from $384.00 to $440.00 and gave the company a “hold” rating in a research note on Wednesday, November 4th. Barclays lifted their price target on shares of Amgen from $400.00 to $430.00 and gave the company an “equal weight” rating in a research note on Monday, November 16th. Finally, BMO Capital Markets dropped their price objective on shares of Amgen from $450.00 to $415.00 and set a “market perform” rating on the stock in a report on Monday, October 12th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $428.62.
View Our Latest Research Report on AMGN
Amgen Profile
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
See Also
- Five stocks we like better than Amgen
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
